Vergoeding 2019-2023 voor ATC-subgroep R03DX : Overige middelen bij astma/copd voor systemisch gebruik
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022* | 2023* | |
|---|---|---|---|---|---|
| R03DX05 Omalizumab | 33.282.867 | 37.814.820 | 35.523.918 | 36.237.560 | 39.362.677 |
| R03DX08 Reslizumab | 3.009.792 | 3.032.737 | 2.729.678 | 2.385.567 | 2.204.945 |
| R03DX09 Mepolizumab | 16.559.668 | 18.889.323 | 18.570.201 | 19.479.397 | 22.909.964 |
| R03DX10 Benralizumab | 8.278.467 | 12.246.371 | 13.861.906 | 16.148.818 | 17.179.488 |
| R03DX11 Tezepelumab | . | . | . | . | 44.568 |
| Totaal | 61.130.794 | 71.983.252 | 70.685.703 | 74.251.342 | 81.701.642 |